HRH-ZY200 Sample Tube Agitation System for Inhalation Drug Delivery Uniformity Testing

Overview

The HRH-ZY200 Sample Tube Agitation System is an engineered solution designed specifically for pharmaceutical laboratories conducting dose uniformity testing of inhaled drug products in accordance with pharmacopoeial and regulatory standards—including USP , EP 2.9.18, and ISO 27427. It operates on the principle of controlled mechanical agitation to facilitate complete and reproducible dissolution of deposited active pharmaceutical ingredient (API) from inhalation sampling tubes—such as Andersen cascade impactor (ACI) collection stages, Next Generation Impactor (NGI) cups, and proprietary pMDI/DPI test tubes—into a defined solvent volume. Unlike manual shaking or vortexing, the HRH-ZY200 delivers quantifiable, programmable motion profiles (oscillation, rolling, or combined), ensuring consistent energy input across replicate runs. This eliminates inter-operator variability and supports GLP-compliant workflows where traceability, repeatability, and audit readiness are essential.

Key Features

• Triple-mode agitation control: Independent selection of oscillation-only, rolling-only, or synchronized oscillation-plus-rolling motion—each fully parameterizable via intuitive 7-inch capacitive touchscreen interface.
• High-resolution motion calibration: Oscillation frequency adjustable in 1-cycle increments from 20 to 200 cycles/min; rolling speed tunable in 0.1-rpm steps from 10 to 20 rpm—enabling precise matching to formulation-specific solubilization kinetics.
• Universal tube accommodation: No clamps, fixtures, or adapters required—standard pMDI actuator tubes (e.g., USP Class I/II), DPI throat models, NGI collection cups (stages 0–7), and pressure-port-equipped DPI test tubes rest securely on the non-slip, chemically resistant stainless-steel tray.
• Robust thermal and mechanical architecture: Aluminum alloy frame with vibration-dampening rubber feet; sealed IP54-rated electronics; continuous-duty motor rated for 500 hours cumulative runtime without performance degradation.
• Regulatory-ready operation: All parameter settings, start/stop timestamps, and mode selections are logged internally with UTC synchronization—supporting 21 CFR Part 11–compliant data integrity when integrated with validated LIMS or electronic lab notebook (ELN) systems.

Sample Compatibility & Compliance

The HRH-ZY200 is validated for use with standard inhalation sampling geometries per USP and ISO 27427 Annex A. It accommodates tubes up to 120 mm in height and 30 mm in diameter—including glass and polypropylene variants—and maintains positional stability during high-frequency oscillation. The device does not alter sample temperature or introduce aerosolization risk, preserving analyte integrity. Its motion profile consistency meets the “mechanical equivalence” requirement outlined in FDA Guidance for Industry: *Quality Attributes of Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Products* (2022). Routine verification can be performed using calibrated digital tachometers and cycle counters—documentation templates available upon request for IQ/OQ/PQ protocols.

Software & Data Management

The embedded firmware supports parameter saving in named method files (.hrh), each storing full motion configuration (mode, frequencies, duration, ramp profiles), operator ID, and date/time stamp. Up to 99 methods may be stored locally. USB-C port enables encrypted export of session logs (CSV format) containing timestamped motion events, error codes, and runtime diagnostics. Optional RS-485 Modbus RTU interface allows integration into centralized QC automation platforms. Audit trail functionality records all user actions—including method edits, password resets, and firmware updates—with immutable timestamps and user attribution—fully aligned with ALCOA+ principles and GMP Annex 11 requirements.

Applications

• Dose uniformity testing of pressurized metered-dose inhalers (pMDIs) per USP Stage I–III procedures.
• Drug recovery optimization from dry powder inhaler (DPI) sampling tubes, including multi-stage impactor substrates (ACI, NGI, EDA).
• Method development for poorly soluble APIs requiring extended or dual-mode agitation to achieve quantitative extraction.
• Comparative dissolution studies between generic and reference-listed drugs under identical mechanical conditions.
• Supporting QbD-based process validation by establishing robust agitation parameters linked to recovery % RSD ≤ 3.0% (n = 6) across multiple batches.

FAQ

Does the HRH-ZY200 meet FDA or EMA regulatory expectations for automated agitation in inhalation product testing?
Yes—it satisfies the instrumentation control and data integrity criteria specified in FDA’s 2022 MDI/DPI guidance and EMA’s CHMP Reflection Paper on Quality of Inhalation Products, provided it is operated within validated method ranges and maintained per manufacturer-recommended intervals.
Can the device be qualified for GMP environments?
Yes—comprehensive IQ/OQ documentation packages (including test scripts, acceptance criteria, and blank forms) are available. PQ execution requires site-specific formulation testing but is supported by built-in calibration traceability and event logging.
Is solvent evaporation minimized during prolonged agitation cycles?
The system operates at ambient temperature with no active heating or cooling; however, covered tube configurations (e.g., crimp-caps or Parafilm® seals) are recommended for >30-minute runs to limit volatilization—consistent with USP Section 5.3.
What maintenance is required to ensure long-term motion accuracy?
Biannual verification of oscillation frequency and rolling speed using NIST-traceable tachometry is advised; lubrication-free direct-drive motors eliminate routine greasing requirements.
Is remote monitoring or control possible?
Local touchscreen operation is standard; Ethernet or Wi-Fi connectivity is not natively supported, but Modbus-enabled SCADA integration permits status polling and alarm triggering via external PLCs.